Böhm W, Klinger G, Carol W, Hempel E
Zentralbl Gynakol. 1977;99(7):385-91.
Endometrium was investigated histologically in 55 fertile women and by electron-microscope in 6 women under the influence of Deposiston (Jenapharm), a sequential contraceptive containing a long acting oestrogen--ethinyloestradiolsulfonate. The drug was administered orally in 1 mg doses on the 5., 12. and 19. day of each cycle. To achieve proper withdrawal bleeding a single oral dose of 10 mg norethisteronacetate was given on the 26. day of the cycle. Whereas Sequenz- Ovosiston (Jenapharm), a "classical" sequential preparation causes only insignificant variations from the physiological endometrium of fertile women, Deposiston developes irregularly proliferated patterns in more than 50% of the patients, due to differences of the elimination rate of ethinyloestradiolsulfonate. The degree of proliferation covers a wide range from a slightly proliferated endometrium to changes similar to hyperplasia of the endometrium with cystically enlarged glands. The secretory transformation takes place 2 or 3 days following the progestogen application. In 2 of the cases a secretory pattern could be found several days before the intake of the progestogen. This indicates break-through-ovulations.
对55名育龄妇女的子宫内膜进行了组织学研究，并对6名服用Deposiston（耶拿药厂生产）的妇女进行了电子显微镜检查。Deposiston是一种序贯避孕药，含有长效雌激素——乙炔雌二醇磺酸盐。在每个周期的第5、12和19天口服1毫克该药物。为了实现适当的撤退性出血，在周期的第26天口服单剂量10毫克醋酸炔诺酮。“经典”序贯制剂Sequenz - Ovosiston（耶拿药厂生产）与育龄妇女的生理性子宫内膜相比仅引起微小变化，而Deposiston由于乙炔雌二醇磺酸盐消除率的差异，在超过50%的患者中出现不规则增殖模式。增殖程度范围广泛，从轻度增殖的子宫内膜到类似于子宫内膜增生伴腺体囊性增大的变化。在应用孕激素后2或3天发生分泌期转化。在2例病例中，在摄入孕激素前几天就发现了分泌期模式。这表明出现了突破性排卵。
